Formulation Development and Evaluation of Opthelmic IN SITU Gelling Systems of TIMOLOL MALEATE
Loading...
Date
item.page.authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
he present investigation is aimed to develop and evaluate safe, effective,
newlineand stable ophthalmic stimuli-responsive in-situ hydrogel using the
newlinecombination of ion-responsive polymer gellan gum and pH-sensitive polymer
newlinecarbopol 934P and the microemulsion (ME) based phase transition\liquid
newlinecrystalline (LC) in-situ ocular gelling system for delivery of Timolol maleate in
newlinethe treatment of glaucoma.
newlineThe selected model drug Timolol maleate (TM) belongs to BCS class I and is
newlinethe first line treatment in open angle glaucoma. The drug gets rapid precorneal
newlineelimination from conventional formulation. The present study
newlineaddresses this issue with two formulation development strategies i.e., stimuliresponsive
newlinein-situ gelling system and ME based LC in-situ gelling system.
newlineThe present study explores development of stimuli-responsive in-situ gelling
newlinesystem with the combined use of ion sensitive gellan gum and pH
newlinesensitive/muco-adhesive Carbopol. It is the first attempt of development of
newlineocular drug delivery system using gellan gum and carbopol combination by
newlineexperimental design. We have used Box-Behnken design to statistically
newlineoptimize the formulation parameters and evaluate the effects of formulation
newlineattributes, namely concentration of gellan gum, the concentration of carbopol
newline934P and concentration of benzododecenium bromide on selected critical
newlinequality attributes. Trial run data were analysed using the polynomial equation
newlineand response surface plots. Optimized formulation was selected based on
newlinedesirability function, design space. The cross-linking between carbopol 934P
newlinewith gellan gum in the formation showed more viscous gelling at the
newlinephysiological condition to provide long pre-corneal residence time. Trial runs
newlineshowed controlled drug release with diffusion-controlled mechanism and good
newlinemucoadhesive strength. The preservative benzododecenium bromide showed
newlinethe ability to enhance trans-corneal permeation. The optimized formulation
newlineselected based on design space has appeared as a clear solution at the nonvii
newlinephysiological condition